Glaukos Co. (NYSE:GKOS) COO Sells $316,156.75 in Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 2,275 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Glaukos Stock Down 0.4 %

Shares of NYSE:GKOS opened at $131.77 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48. The company has a market cap of $7.24 billion, a PE ratio of -40.42 and a beta of 1.02. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $139.51. The firm has a 50 day simple moving average of $129.68 and a 200 day simple moving average of $119.57.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GKOS. Citigroup lowered shares of Glaukos from a “buy” rating to a “neutral” rating and upped their price target for the stock from $130.00 to $132.00 in a research note on Wednesday, July 10th. Needham & Company LLC increased their target price on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Morgan Stanley increased their target price on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Stifel Nicolaus increased their target price on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Truist Financial increased their target price on shares of Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and a consensus price target of $130.45.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GKOS. Values First Advisors Inc. acquired a new position in Glaukos in the 3rd quarter valued at approximately $25,000. GAMMA Investing LLC increased its stake in Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 486 shares during the period. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos in the 2nd quarter valued at approximately $187,000. Brighton Jones LLC acquired a new position in Glaukos in the 2nd quarter valued at approximately $208,000. Finally, Procyon Advisors LLC acquired a new position in Glaukos in the 3rd quarter valued at approximately $210,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.